WFG Scleral Lenses for Keratoconus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Keratoconus+7 More
Wavefront Guided Scleral Lenses - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new type of contact lens that may help improve vision for people with certain eye conditions.

Eligible Conditions
  • Keratoconus
  • Cornea
  • Pellucid Marginal Corneal Degeneration
  • Wavefront Aberration, Corneal
  • Irregular Astigmatism
  • Keratoglobus

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 4 weeks

4 weeks
Contrast Sensitivity
Higher order aberration
Visual Acuity

Trial Safety

Trial Design

2 Treatment Groups

WFG Scleral Lenses
1 of 2
Traditional Scleral Lenses
1 of 2
Active Control
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: WFG Scleral Lenses · Has Placebo Group · N/A

Traditional Scleral Lenses
Device
PlaceboComparator Group · 1 Intervention: Traditional Scleral Lenses · Intervention Types: Device
WFG Scleral Lenses
Device
ActiveComparator Group · 1 Intervention: Wavefront Guided Scleral Lenses · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 weeks

Who is running the clinical trial?

Cornea and Laser Eye InstituteLead Sponsor
9 Previous Clinical Trials
1,013 Total Patients Enrolled
9 Trials studying Keratoconus
1,013 Patients Enrolled for Keratoconus
John D Gelles, ODPrincipal InvestigatorThe Cornea and Laser Eye Institute

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: October 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.